Acrivon Therapeutics Presents Data at AACR Annual Meeting Hi

Acrivon Therapeutics Presents Data at AACR Annual Meeting Highlighting the Capabilities of Acrivon Predictive Precision Proteomics (AP3) for the Discovery of ACR-2316, a Novel, Selective WEE1/PKMYT1 Inhibitor, and the Identification of Actionable Resistance Mechanisms to ACR-368

ACR-2316, which was internally discovered using biological SAR enabled by AP3 to overcome limitations of benchmark clinical WEE1 and PKMYT1 inhibitors, demonstrates potent anticancer activity in...

Related Keywords

United States , American , Alexandra Santos , Peter Blume Jensen , Exchange Commission , Drug Administration , Acrivon Therapeutics Inc , American Association For Cancer Research , Acrivon Predictive Precision Proteomics , American Association , Cancer Research , Fast Track , Breakthrough Device , Private Securities Litigation Reform Act , Media Contacts , Markets ,